NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VR
Post# of 26
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018. Highlights include the company’s ongoing search for prospective office and research lab space on the campus of the University of British Columbia, its subsidiary’s progress toward the commencement of human trials in Puerto Rico studying lead cannabis strain CTL-X for pain management, its reception of a Health Canada dealer license through subsidiary Cannevert Therapeutics Ltd. (“CTL”) and CTL’s initiation of a cancer research project aimed at assessing the effects of several human cancer cell lines against cannabis strains, among others.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer